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Itremainsunclearwhichchildrenandadolescentswithresectednonrhabdomyosarcomasofttissuesarcoma(NRSTS)beneﬁtfrom
radiation therapy, as well as the optimal dose, volume, and timing of radiotherapy when used with primary surgical resection.
This paper reviews the sparse literature from clinical trials and retrospective studies of resected pediatric NRSTS to discern local
recurrence rates in relationship to the use of radiation therapy.
1.Introduction
NRSTS in the pediatric age group is a challenging group of
tumors to manage due to a variety of reasons, particularly
for the radiation oncologist. The diversity of histologic
subtypesmayinﬂuencethesensitivityoftumorstoradiation.
The spectrum of anatomical sites may preclude a complete
marginal resection in certain sites, which in turn inﬂuences
the dose of radiation needed to control disease. The patterns
of local tumor spread also inﬂuence the optimal treatment
volume. Additionally, the uncommon occurrence of pedi-
atric NRSTS, which is only approximately 500 cases per year,
and the wide age distribution from infancy to adulthood
add to the challenges of determining appropriate radiation
dose, volume, and timing relative to surgical resection [1].
Many radiation oncologists reference guidelines established
for adult soft tissue sarcomas for radiation therapy dose
and volume based on sarcoma grade, tumor size, and resec-
tability. However, patients in the pediatric age group are
unique from adults for many reasons including growth and
fertility considerations and longer life span to develop late
eﬀects of radiation including an enhanced risk for second
malignant tumor induction.
Radiation therapy dose and volume guidelines for
rhabdomyosarcoma (RMS), the most common soft tissue
sarcoma in childhood, have been established through a series
of phase III prospective trials conducted over 4 decades by
the Intergroup Rhabdomyosarcoma Study Group (IRSG)
and COG [2–5]. Similar trials have not been conducted
for the pediatric NRSTS. As no standard of care currently
exists for managing this diverse group of tumors, the current
challenge for children with soft tissue sarcoma, other than
rhabdomyosarcoma, is to identify which patients beneﬁt
from the addition of radiation therapy and to determine the
lowest optimal radiation dose and volume to be adminis-
tered, so as to avoid injury to normal tissues and minimize
risk for the development of a second cancer.
2. Who Beneﬁts from Adjuvant Radiation
Therapy for Resectable PediatricNRSTS?
Patients with resectable soft tissue sarcoma are known to
have a superior outcome as compared with those having
a tumor which is not initially resectable. Patients with a
sarcoma resected at the time of diagnosis have an estimated
5-year survival rate 89% as compared to those whose tumor
is unresected at diagnosis, with 5-year survival estimated to
be just 60% [6, 7]. Although complete surgical resection is
the cornerstone to curative therapy in pediatric NRSTS, the2 ISRN Oncology
question for the radiation oncologist is whom of those with
resectablediseasewillfaillocallyandthusmightbeneﬁtfrom
the addition of radiation therapy.
The answer to this question is complex and multi-
factorial. The only United States multicenter trial for
resectable pediatric NRSTS was conducted through the
Pediatric Oncology Group (POG) from 1986 to 1993.
Although this POG 8653 trial was designed to test the
eﬃcacy of adjuvant chemotherapy in resectable pediatric
NRSTS, the radiation therapy guidelines provide insight as
to the evolution of treatment recommendations. Group I
patients with completed resected disease did not receive
postoperative radiation. Group II patients with microscopic
residual disease received postoperative radiation therapy
basedontheirageandpotential forgrowth. Patients younger
than 6 years of age received 35Gy followed by a ﬁeld
reduction to a total dose of 45Gy. Those 6 years and older
received 45Gy followed by a ﬁeld reduction to a total dose of
50Gy. Although outcome data was not reported separately
for the Group I (55 patients) and Group II (25 patients),
the analysis suggests that among 80 patients, there were
8 patients with a local recurrence (12.5%) with at least 5
occurring in Group I patients who did not receive radiation;
the majority of these were high grade tumors. The most
importantﬁndingofthisstudywasthatPOGgrade3tumors
faredmuchworse(52%survivalat5years)ascomparedwith
POG grade 1 or 2 sarcomas (92% 5-year survival) deﬁning
tumor grade as an important prognostic factor inﬂuencing
outcome [8, 9].
TheIRSGclinicalgroupingclassiﬁcationthatwasusedto
stage patients on this trial is frequently used today. However,
it has not been validated as a universally accepted or an
appropriate staging system for pediatric NRSTS as it does
not account for important factors, such as tumor grade and
depthofclearsurgicalmargins.Forexample,thewidthofthe
normal tissue from inked surface of the surgical specimen
to viable tumor is not speciﬁed in this classiﬁcation, only
that a “cuﬀ of normal tissue” is required to allocate patients
into Group I. Group II included patients with microscopic
positive margins [10].
We know from retrospective single institution studies
that for completely resected tumors, the width of a clear
surgical margin inﬂuences the local recurrence rate. Blakely
et al. reviewed the St. Jude Children’s Research Hospital
experience of 88 children with NRSTS in which the IRSG
classiﬁcation was used in Group I patients to determine
the local recurrence rate in relationship to the width of the
pathologic surgical margin. Patients whose tumors revealed
a surgical margin of ≥1cm had fewer local recurrences
regardless of tumor grade. Those with a surgical margin
<1cm and low-grade histology did not beneﬁt from routine
postoperative radiation, whereas patients with a high-grade
tumor had improved local control with postoperative radi-
ation therapy. Of 14 patients with a <1cmsurgicalmargin
and high grade tumors, 7 had postoperative radiotherapy,
and no recurrences were observed, whereas of the 7 patients
who did not receive postoperative radiotherapy, 3 (42.9%)
suﬀered a local recurrence. Of 20 patients with at least a
1cm negative surgical margin and a high grade tumor, none
received postoperative RT and 4 recurred (20%). This report
suggestedthatradiationtherapymostbeneﬁtsthosewithless
than a 1cm margin and those with a high-grade tumor [11].
Spunt et al. extended the St. Jude Children’s Research
Hospitalexperience assessingprognostic factorsforpediatric
patients presenting with resectable NRSTS and analyzed
121 patients treated between 1969–1996. Of 81 Group I
patients,61hadatleast1cmsurgicalmargin,whereas20had
less than 1cm margin. Only 10 patients received adjuvant
radiation therapy with a median dose of 54.9Gy (range
26.5 to 60.4Gy). Univariate analysis showed that the width
of the margin did not inﬂuence local recurrence nor did
the addition of postoperative radiation for the small group
(10%) who received radiation therapy. However, almost 60%
of the Group I patients had low-grade (POG grade 1and
2) tumors. Of 40 Group II patients, 21 patients received
radiation therapy with a higher median dose of 59.4Gy
(range of 40 to 75Gy). The 5-year estimated cumulative
incidence of local failure was 12.8% for Group I and II
patients. 17 of 121 patients had a local recurrence only.
Two patients relapsed with both local and distant disease.
Factors associated with local recurrence were microscopic
residual disease, large tumor size, and intra-abdominal
disease, whereas improved local control was associated with
the use of radiation therapy. Of note, these authors report
that of 76 low-grade tumors, 10 recurred (13%), but 9
patients were alive with retreatment with only one patient
death, from a radiation-induced osteosarcoma [7].
Although this retrospective review suggested that margin
width for patients with Group I tumors did not inﬂuence
outcome, the authors attributed this to the relatively small
percentage of high-grade tumors in this cohort and a large
proportion having at least a 1cm negative surgical margin.
For those with a Group II tumor, the administration of
radiation reduced the local recurrence rate. It is important
to note that the median radiation dose was 59.4Gy, higher
than used on the POG 8653 trial (45–50Gy).
Smithetal.reportedtheoutcomeof95resectableNRSTS
pediatric and young adult patients treated at the University
of Florida over a 34-year period. All patients in this series
received radiation therapy, either preoperatively (median
dose 50.4Gy, range 27–69.6Gy) or postoperatively (median
dose of 61Gy, range 37.5–74.4Gy). Although there is not
a comparative cohort who did not receive radiotherapy,
there are several interesting lessons from this experience.
The Florida investigators used ≥1cm as their institutional
deﬁnition of a negative margin versus <1cm as a close
margin and considered microscopic residual disease as a
positive margin. They reported an overall local failure rate
of just 12% at 5 years. Patients with a negative margin had a
statistically signiﬁcant higher local control rate at 5 years by
univariate and multivariate analyses with only 4 of 64 (6%)
local recurrences observed versus 8 of 30 (27%) when the
margin was close or positive. The authors did not observe
an association of grade with local recurrence; however they
had a small number of patients with a low-grade tumor
who received radiotherapy, reﬂecting the institutional policy
of carefully selecting patients in whom radiation therapy
might be avoided. Of note, the authors reported that allISRN Oncology 3
patientswhosuﬀeredalocalfailureultimatelydiedofdisease
[12].
None of these series are readily comparable, but taken
together they suggest that for patients with a completely
resected tumor, deﬁning the width of a negative surgical
margin is an important factor in determining who will
beneﬁt from the addition of radiation therapy. In the
pediatric and young adult population it is often challenging
to achieve a 1cm surgical margin, simply due to the relative
lackoftissueascomparedwithanadult.Additionally,certain
primary sites, such as the head and neck and retroperitoneal
region, may be very diﬃcult anatomic regions to achieve a
clear margin. Therefore, lesser margins are often accepted
in the pediatric and young adult age group, as compared
with adults. The current Children’s Oncology Group (COG)
NRSTS trial for pediatric and young adults is prospectively
testing whether 0.5cm or greater in all directions around
the tumor and/or tumor abutting the fascia or periosteum
that is removed in continuity with the tumor specimen is an
appropriate negative surgical margin.
3. Other Prognostic Factors to Consider for
the Use of AdjuvantRadiation Therapy
Histologic grade of tumor also has prognostic value for
determining if the addition of radiation therapy may beneﬁt
thosewithahigherriskforlocalrelapse.Twogradingsystems
commonly used in pediatric soft tissue sarcomas are a POG
grading system and the French Federation of Cancer Centers
(FNCLCC) grading system. The POG system is based on
histologic type, necrosis, and mitosis, whereas the French
Federation of Cancer Centers (FNCLCC) grading system is
based on diﬀerentiation, necrosis, and mitosis [9, 13, 14].
Whether one grading system is superior for predicting
outcome is unknown. However, it is important to know
which grading system is used when reviewing retrospective
series with regard to local recurrence and distant metastases.
For example, in Spunt’s retrospective analysis of prognostic
factors in pediatric NRSTS, POG grade 1 and 2 tumors were
combined into a low grade group and compared with POG
grade 3 high-grade tumors. This subdivision is supported by
the results of the prospective POG 8653 trial analysis which
showedsimilarsuperioroutcomesforthePOGgrade1and2
tumors as compared with poorer outcome for high grade—
POG grade 3 tumors. In Spunt’s series, no patients with a
low-grade tumor died of disease despite withholding post-
operative radiation therapy for those patients with a close
or a positive margin (Group I or Group II). Taken together
these data support including intermediate POG grade 2 into
alowergradecategory[7].Theimportanceofthisdistinction
isthatdistantmetastasesarerareinpatientswithalow-grade
sarcoma.Thereforelocalrecurrenceaftersurgeryisrarelylife
threatening.Amanagementstrategyofcarefulobservationin
those presenting with a low-grade tumor with close and/or
positive margin is often adopted in an attempt to avoid or
delay the administration of radiation therapy. Reexcision
with possible radiation at the time of recurrence can result
in an excellent overall survival. An exception to this strategy
would be if the location of the primary tumor would require
an amputation or other mutilating procedure if the tumor
does recur locally.
In distinction to the low-grade tumors, resectable high-
grade tumors carry an increased risk for local recurrence and
distant metastases. As noted in the above studies, patients
with a Group II tumor who have a high-grade sarcoma
are shown to have a decreased risk for local recurrence
when adjuvant radiation therapy is administered. Whether
optimizing local control improves overall survival remains
unclear, with some series suggesting a survival beneﬁt when
the local recurrence rate is low [7, 11, 12, 15, 16].
For patients with a Group I high grade sarcoma, in
addition to the margin width, tumor size and invasiveness
also inﬂuence outcome. Ocku et al. reported an association
of unfavorable outcome in those with a resectable synovial
sarcoma with invasiveness and large size (>5cm). In this
multicenter, multivariate analysis of synovial sarcomas in
childhood and adolescence, the results of four large research
groups were analyzed. Both tumor size (>5cm) and invasive
disease (invading contiguous tissue or organs) were prog-
nostically signiﬁcant for poor event free survival (EFS) and
overall survival (OS) in those patients with a Group I or II
disease. Of these Group I and II patients, only univariate
analysisconﬁrmedanassociationwithaninvasivetumorand
a higher risk of local recurrence. When radiation therapy
was delivered, the median dose was 50Gy with a range
from 16 to 68Gy. When the impact of radiation therapy
o nl o c a lr e c u r r e n c ef r e es u r v i v a lw a se v a l u a t e d ,t h e r ew a s
not a statistically signiﬁcant local recurrence free survival
beneﬁt whether patients received radiation therapy (96% at
5 years) compared to those in whom it was omitted (87% at
5 years). The authors hypothesize that the small number of
local recurrences or possible misclassiﬁcation of Group I and
II patients could contribute to the noted lack of beneﬁt from
radiation therapy [15].
The analysis by Orbach et al. provides an opportunity
to review the results of a treatment strategy designed to
avoid radiation therapy in young patients with localized
synovial sarcoma. Pooling three prospective trials on pedi-
atric patients with synovial sarcoma conducted from 1984 to
2003throughtheInternationalSocietyofPediatricOncology
Malignant Mesenchymal Tumor study (SIOP-MMT), there
were 21 IRS Group I patients with synovial sarcoma. Only
2 patients received postoperative radiotherapy, with a dose
of 45Gy recommended on all 3 trials. There were 3 local
recurrences (15%), all occurring in patients who did not
receive radiation, and all were alive without disease at the
study report. The 2 patients who received radiotherapy had a
metastatic relapse and both died of disease. Although the 5-
year EFS was 69% for Group I patients, the OS at 5 years was
90%, leading the authors to conclude that radiation therapy
could be omitted in this population of patients. This series
suggests that for completely resected synovial sarcomas, local
failuredoesnotportendaworseoutcomeasretreatmentma y
be successful [17].
Of note, synovial sarcomas are generally regarded as
high-grade sarcomas; however, this remains an unresolved
pathologic controversy. If a tumor has some intermediate4 ISRN Oncology
grade features, a more favorable outcome might be expected
which may inﬂuence the recommendation regarding adju-
vant therapy [18]. Ladanyi et al. report that the molecular
signature of the SYT-SSX fusion type provides the strongest
prognostic information for localized synovial sarcoma com-
pared with all other prognostic factors including histologic
grade, age, sex, and anatomic location [19]. Pathologic and
molecular research will continue to enhance our knowledge
of appropriate therapy when there may be a discrepancy
between morphology and molecular analysis.
Another common NRSTS in the pediatric and young
adolescent age group is malignant peripheral nerve sheath
tumor (MPNST). These tumors have a predilection for local
recurrence and distant metastases with poorer OS than that
seen in synovial sarcoma. Patients with neuroﬁbromatosis
1 (NF1) who develop MPNST have a poorer prognosis as
compared with patients without NF1. Carli et al. reported
the results of patients with MPNST treated in Italian and
Germanstudiesbetween1975and1998.Theanalysisshowed
progression free survival (PFS), and OS for Group I was 61%
and 82%, whereas Group II was 37% and 62%, respectively.
25% of Group I patients received adjuvant radiation therapy
with a local recurrence rate of just 17%. For those Group I
patients in whom radiation therapy was omitted, the local
recurrence rate was 36%. For Group II patients, the local
recurrence rate with radiation therapy was 45% versus 68%
without radiation therapy. The radiation dose in this study
population was 45Gy using a hyperfractionated treatment
with 1.6Gy given twice daily [20]. This series suggests that
local control is a critical problem, even for completely
resected disease suggesting an inherent biologic resistance to
current therapy.
Many soft tissue sarcomas in the pediatric and young
adult age group are unable to be histologically subtyped
withcurrentimmunohistochemistrystainsandsophisticated
molecular testing and are hence labeled as unclassiﬁed or
undiﬀerentiated NRSTS. The IRSG trials included undiﬀer-
entiated sarcomas in their studies. Although undiﬀerentiated
sarcoma accounted for a small proportion (4%) of the total
eligible patients on IRS IV, the 3-year EFS was statistically
inferior (55%) when compared with similar therapy for
alveolar RMS (66%) and embryonal RMS (83%). On this
trial, Group I patients did not receive radiation therapy
unless they had pretreatment poor prognostic features
(unfavorable site and either clinical evidence of regional
node involvement or an invasive tumor), in which case
they received 41.4Gy. All Group II patients received 41.4Gy
[4]. In current RMS trials conducted through COG soft
tissue sarcoma committee, undiﬀerentiated or unclassiﬁed
sarcomas are ineligible histologic subtypes for study entry,
but are included as a histologic subtype eligible for a NRSTS
trial.
Age may inﬂuence the decision to recommend adjuvant
radiation therapy. Hayes-Jordan et al. reported young age as
a favorable prognostic factor for pediatric NRSTS. Improved
outcome was attributed to younger patients having smaller,
lower-grade tumors with less invasive characteristics, such
as myxoﬁbrosarcoma, with no patients less than 1 year of
agewithmetastaticdiseaseatdiagnosis.Comparatively,older
patients (>1 5y e a r so fa g e )w e r em o r el i k e l yt oh a v eh i g h e r
grade, more invasive sarcomas, such as synovial sarcoma
and MPNST, and more advanced disease at diagnosis [21].
Even within the same histologic subtype older age appears
to remain a poor prognostic factor. Okcu et al. in their
series on synovial sarcoma report this eﬀect of age, with
younger patients faring better than those diagnosed at an
older age [15]. Age may possibly be used as a factor for
withholding radiation or reducing the radiation dose in
certain youngsters presenting with a resectable high-grade
tumor where the latent long-term risks associated with the
addition of radiation therapy may outweigh the beneﬁt of
such therapy.
An additional concern when considering the admin-
istration of radiation therapy may be the predilection of
the patient to develop a second cancer as a result of
carrying an underlying germline mutation where ionizing
radiation may upregulate critical molecular pathways asso-
ciated with tumorigenesis. One of the more common non-
rhabdomyosarcomas in the pediatric age group, MPNST, has
been associated with underlying germline mutation in NF1
in about 50% of patients. An array of NRSTS tumors are
associatedwithagermlinemutationsuchasP53(asobserved
in patients with the Li-Fraumeni syndrome) where exposure
to radiation is associated with an increased risk for causing a
latent secondary cancer [22].
4. Radiation Therapy Dose, Volume,
andTreatment Techniques
Despite the attendant risks associated with treatment, some
patients with resectable pediatric and young adult NRSTS
beneﬁt from the administration of radiation. As the desired
goal of radiation therapy is to optimize local control with a
minimal eﬀect on quality of life, several diﬀerent strategies
may be considered. Patients with subclinical disease may not
require the same radiation dose as those who clearly have
microscopic residual disease. Modifying the radiation dose
according to extent of disease is a concept well known to
radiation oncologists since Fletcher proposed a graduated
dose scheme for adults with head and neck carcinoma to
sterilize subclinical lymph nodes versus a higher dose to treat
a primary site with microscopic or gross disease. Doses of
50Gy were recommended for subclinical disease, 60Gy for
microscopic disease, and 70Gy for gross disease [23]. Using
a similar paradigm, it may be feasible to use a lower dose in
thesettingofaclearlynegativemargin,suchas45–50Gy,and
a slightly higher dose of 50–55Gy for a true microscopically
involved margin.
In addition, the POG 8653 trial, which adjusted the
radiation dose according to age, is supported by data
suggestingyoungerchildrenfarbetterthanolderadolescents,
even within the same histologic subtype, such as seen in
synovial sarcoma.
Better understanding of which sarcomas are more likely
to be radiosensitive, through analysis of the pathologic
treatment eﬀect in patients who have received preoperative
radiation therapy, may allow dose adjustment. For example,ISRN Oncology 5
Roberge et al. reported on the imaging and pathologic
response of radiation therapy for extremity and truncal
soft tissue sarcomas in 50 patients. This report showed an
association between reduction in tumor volume by imaging
predictive of a pathologic treatment response in the surgical
specimen. Some histologic subtypes were shown to be very
radiation therapy sensitive, such as myxoid liposarcoma,
where a substantial decrease in tumor volume (82.1%) on
imagingwasassociatedwithahighpercentoftumornecrosis
in the pathologic specimen. High-grade sarcoma which
showed very minimal reduction (<1%) in the tumor volume
by imaging was associated with minimal treatment-related
eﬀect seen in the pathologic specimen.
Other strategies to minimize late eﬀects of treatment
might be to consider the use of preoperative radiation
therapy in those patients presenting with a large, invasive,
and high-grade tumor that would likely require radiation
therapy based on the pretreatment evaluation [24]. Pre-
operative radiation has the potential advantage of treating
a smaller volume with lower doses potentially resulting in
fewer complications. A Canadian sarcoma randomized trial
reported fewer long-term complications in patients who
received preoperative radiation therapy as compared with
postoperative therapy [25].
Oneofthemosteﬀectivewaystominimizethelateeﬀects
of radiation therapy is to design the radiation ﬁeld to protect
the adjacent normal tissues. The best way to accomplish
this is to use smaller treatment margins around the tumor
volume. Historically, wide margins up to 5cm or greater
were used to treat potential subclinical disease far beyond the
operative bed or radiographic ﬁndings. In turn, such a large
volume would invariably include critical organs and normal
tissues vital for form and function.
Krasin et al. prospectively tested whether a smaller mar-
gin on the target volume could be used and not compromise
local control. Of 32 pediatric and young adults with a
high-grade NRSTS, 27 received adjuvant radiation therapy.
Using a 2cm margin around the tumor volume at diagnosis
and delivering a median cumulative postoperative radiation
dose of 60Gy (range 41.4–70.4Gy) or a preoperative dose
of 45Gy (range 45–50.4Gy), the 3-year cumulative local
recurrence rate for patients who underwent a marginal or
complete resection was <4%. There were no failures in the
patients with clear surgical margins. Those who failed locally
did so within the high-dose radiation volume, suggesting
limited margin radiation therapy is an eﬀective strategy to
employ in pediatric patients with NRSTS. Techniques such
asthesewouldbeexpectedtoconferlessnormaltissueinjury
includingapossiblereductioninsecondarycancerinduction
[26].
A current COG trial for pediatric and young adults with
NRSTS uses a risk-based stratiﬁcation algorithm tailoring
radiation therapy dose and volume based on tumor grade,
size, and margin status. The results of this trial will hopefully
provide critical answers to whom beneﬁts from adjuvant
radiation therapy.
In order to optimize the delivery of radiation therapy,
immobilization and careful delineation of the target volume
to treat are critical to the successful outcome. The standard
of care today is to include 3 dimensional (3D) volumetric
planning using cross-sectional imaging by either computed
tomographic (CT) or magnetic resonance imaging (MRI).
Eﬀective immobilization techniques provide the ability to
deliver extremely conformal treatment. Additionally, sar-
comas located in the chest or abdomen may shift with
diaphragmatic motion during radiation therapy. Accounting
forrespiratorymovementisnowpossibletoallowforfurther
reﬁnements in the concise delivery of radiation to the target
volume.
Choosing the appropriate preoperative radiographic
imaging study to fuse with a treatment planning CT/MRI
scan is critical, particularly in the postoperative setting
where anatomy of normal structures has returned to nor-
mal position. Furthermore treatment planning systems can
format preoperative images to conform to the patient’s new
treatment position allowing better recreation of the precise
location of the original tumor in relation to normal tissues
and organs.
Delivery techniques, such as intensity modulated radi-
ation therapy (IMRT) allow sculpting the radiation dose
around vital structures. Although IMRT may deliver a higher
integral dose than observed using a conformal 3-D plan,
the shaping and deposition of radiation therapy is more
precise [27]. Particle therapy, such a proton beam therapy,
has been used in pediatric patients at several centers around
the world with reported results showing excellent dosimetric
delineation of target with minimal scatter to normal tissues
and little exit dose. The expectation is that there will be
fewerlateeﬀects[28].Brachytherapyisanotherexcellenttool
to deliver conformal high dose to target volume. Although
wound complications are reported to be higher in the
implanted site using brachytherapy for sarcoma therapy, this
treatment is a potentially daily precision radiation therapy
delivery, and conebeam computed tomography (CBCT)
helps ensure that normal tissues are within millimeters
of the original simulated position. All these contemporary
technologies contribute to keeping the radiation therapy
dose as low as possible and hence minimizing normal tissue
exposure.
5. Conclusion
The recommendation for the administration of radiation
therapy for pediatric and young adults with resected NRSTS
depends on the width of negative margin, tumor grade,
tumor size, invasiveness, histologic subtype, age, and under-
lying genetic conditions such as Li-Fraumeni syndrome.
Most patients presenting with a low-grade tumor can be
observed with careful physical examination and surveillance
cross-sectional imaging. Clinical trials are needed to deﬁne
which of the patients with a completely resected high-grade
tumor may beneﬁt from the use of radiation therapy in
addition to surgical resection. The appropriate radiation
therapy dose may be driven by several factors including age,
extent of subclinical disease versus overt microscopic disease,
tumor histology, size, and invasiveness. Limited volume
radiation using emerging technology to precisely target a
tumor will reduce exposure to normal tissues.6 ISRN Oncology
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